Asclepius International Journal of Scientific Health Science · Mar 13, 2026
Antidiabetic agents and risk of dementia in type 2 diabetes
By Kurihara AB, Arruda MEG, Muniz CL et al.
INTRODUCTION: Dementia is a progressive neurological condition that constitutes a significant public health problem worldwide, with an increasing prevalence driven mainly by population aging and an increase in metabolic factors, particularly type 2 diabetes mellitus (DM2). There is robust evidence that DM2 increases the risk of cognitive impairment and dementia through metabolic, vascular, and inflammatory mechanisms that affect the central nervous system. Therefore, the central question this study aims to investigate is whether different antidiabetic therapies can alter this risk. METHODS: This integrative literature review was conducted through a database search for articles corresponding to the proposed topic. Eligible articles were assessed in full, excluding those that did not fit the study objectives, theses, and dissertations, without counting duplicates. RESULTS AND DISCUSSION: Type 2 diabetes mellitus is linked to an increased risk of cognitive impairment and dementia, a phenomenon that occurs because of metabolic, vascular, and inflammatory changes. Evidence from observational studies, clinical trials, and meta-analyses indicates that various classes of antidiabetic drugs may have different effects on cognitive outcomes. GLP-1 agonists, SGLT-2 inhibitors, and glitazones are more associated with cognitive profiles that may be favorable, whereas metformin, DPP-4 inhibitors, sulfonylureas, and insulin show more varied results across the studies reviewed. CONCLUSIONS: The findings indicate that GLP-1 agonists, SGLT-2 inhibitors, and glitazones have a more robust association with a possible cognitive benefit, whereas metformin, DPP-4, sulfonylureas, and insulin have effects that vary or are neutral. Thus, pharmacological management of DM2 may have an impact on cognitive prognosis, but because of the diversity of the evidence, prospective studies are needed to confirm the causal relationship and its safety for clinical practice.